Highlights to be presented at Novo Nordisk’s Capital Markets Day 2022

Bagsværd, DenotMark, 3 March 2022 – Novo Nordisk is hosting a Capital Markets Day (CMD) today where the company provides an update on the progress of its 2025 strategic aspirations.

The 2025 Strategic Aspirations were introduced in 2019 to reflect broad aspects of Novo Nordisk’s business, including purpose and sustainability (ESG), opportunities for sustained growth through 2025 across therapeutic and geographic areas as well as Novo Nordisk’s future growth engines in research and development. pipeline.

The day will focus on strategic aspirations and during the day senior management presentations will cover corporate strategy and early research and development strategy, environmental, social and governance (ESG) strategies and performance as well as business strategies, research and development pipeline and performance within Diabetes Care, Obesity Care and Biopharm, which is renowned in rare diseases. In addition, Novo Nordisk’s approach to cardiovascular disease, product supply and finance is presented.

The CMD will also include breakout sessions covering technology platforms, non-alcoholic steatohepatitis (NASH) and Alzheimer’s disease (AD) and the EMEA region.

The highlights of the day are:

  • Focus on securing growth beyond semaglutide by leveraging core research capabilities and new technology platforms
  • Growth potential of GLP-1-based semaglutide therapies in the management of diabetes and prospects for the Phase 3 clinical program for Icodec insulin for weekly administration
  • Launch the update for Wegovy® in the United States, where it is still expected to be able to meet demand in the second half of 2022, an updated commercial strategic aspiration for obesity care and an update of the research and development pipeline on obesity, including semaglutide 2.4 mg cardiovascular outcome trial, SELECT
  • Update on Sustained Growth Aspiration for Rare Diseases and Clinical Trial Results of the Phase 3 Trial with Sogroya® in children with growth hormone deficiency, the results of the phase 1/2 trial with Mim8 in hemophilia A as well as the results of the phase 3 clinical trial with concizumab in people with hemophilia A and B with inhibitors which was successfully completed in February 2022.

All CMD sessions are webcast live and a replay will be available in the investors section of novonordisk.com. CMD presentation material will also be available throughout the day in the investors section of novonordisk.com.

AAbout Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and based in Denmark. Our goal is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do this by paving the way for scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs approximately 47,800 people in 80 countries and markets its products in approximately 170 countries. Novo Nordisk B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchangeage (NVO).

More information

Company Announcement No. 19 / 2022